Acute decompensated heart failure

PercAssist Announces First Patient Treated in EUREKA Study of PSCA System for Hemodynamic Support in Chronic Heart Failure

Retrieved on: 
Thursday, September 28, 2023
Technology, Medical Devices, Clinical Trials, Cardiology, Software, Hardware, Health, General Health, Data Management, Acute decompensated heart failure, Heart failure, Cardiogenic shock, Heart, Pivotal trial, Cardiac output, Trial of the century, PSCA, Patient, IDE, EUREKA, FESC, Medical device, Pharmaceutical industry

PercAssist, Inc ., a medical device company developing innovative technology for a minimally invasive, extravascular platform to provide hemodynamic support for chronic heart failure patients, today announced the successful completion of its first patient in the EUREKA First-in-Human clinical study.

Key Points: 
  • PercAssist, Inc ., a medical device company developing innovative technology for a minimally invasive, extravascular platform to provide hemodynamic support for chronic heart failure patients, today announced the successful completion of its first patient in the EUREKA First-in-Human clinical study.
  • The PSCA System was successfully deployed and provided hemodynamic stability immediately following implantation and throughout the implant period.
  • “We are extremely excited to lead the First-in-Human clinical investigation of the PercAssist PSCA System for chronic heart failure patients requiring hemodynamic support,” said Professor Neuzil.
  • This extravascular ventricular assist technology has tremendous potential for providing hemodynamic support for heart failure patients without the need for anticoagulation therapy.

Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office

Retrieved on: 
Wednesday, August 23, 2023
Patent, Acute decompensated heart failure, IV, Heart failure, Cardiogenic shock, Windtree Therapeutics, HEART, Heart, European Patent Office, LIKE, European Patent Convention, Therapy, Pharmaceutical industry

The new composition of matter patent, titled: “17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE,” provides patent protection through late 2039.

Key Points: 
  • The new composition of matter patent, titled: “17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE,” provides patent protection through late 2039.
  • The newly issued patent follows the Company’s announcement in April 2023 that the European Patent Office granted Patent No.
  • 3599243, which also provides patent coverage for the dual mechanism SERCA2a Activator class of drug candidates.
  • Istaroxime and these follow-on SERCA2a Activators look to deliver on the potential of SERCA2a activation in heart failure.

The Inner Circle Acknowledges, Stephen L. Moore as a Pinnacle Platinum Healthcare Professional for his contributions to the field of Osteopathic Medicine

Retrieved on: 
Monday, August 21, 2023
Heart, Mount Clemens, Michigan, Cardiac electrophysiology, Bachelor, Travel, Osteopathic medicine in the United States, University, FHRS, Education, Internal medicine, American College of Cardiology, Professional, AOBIM, Cardiovascular disease, FACC, Patient, Inner circle, American Osteopathic Board of Internal Medicine, Cooking, Cleveland Clinic, EP, Doctor of Osteopathic Medicine, Bachelor's degree, Acute decompensated heart failure, AVON, Defibrillation, Cardiology, American College, Women's Choice Awards, Triple, Family, Disease, Nursing, Medical device

AVON LAKE, Ohio, Aug. 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Stephen L. Moore is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the field of Osteopathic Medicine.

Key Points: 
  • AVON LAKE, Ohio, Aug. 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Stephen L. Moore is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the field of Osteopathic Medicine.
  • Dr. Moore pursued higher education at the University of Mississippi where he earned a Bachelor's Degree.
  • He then attended Kansas City University of Medicine and Biosciences College of Osteopathic Medicine where he received a Doctor of Osteopathic Medicine degree.
  • Aside from his professional pursuits, Dr. Moore enjoys spending time with his family, cooking, and travel.

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism

Retrieved on: 
Monday, June 12, 2023
Patent, Acute decompensated heart failure, Cardiogenic shock, IV, Windtree Therapeutics, HEART, Heart, European Patent Office, IP, LIKE, European Patent Convention, Therapy, Pharmaceutical industry

A notice of allowance is issued by the USPTO to indicate that the application has passed examination.

Key Points: 
  • A notice of allowance is issued by the USPTO to indicate that the application has passed examination.
  • The Company previously reported that the European Patent Office granted Patent No.
  • 3599243, providing patent coverage for the dual mechanism SERCA2a Activator class of drug candidates.
  • Windtree has preclinical drug candidates with dual mechanisms of action (inhibition of the Na+/K+ pump and activation of SERCA2a) as well as pure SERCA2a activators (devoid of action on the Na+/K+ pump).

Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones

Retrieved on: 
Monday, June 5, 2023
San Francisco, Heart, Acute decompensated heart failure, Cardiogenic shock, Heart failure, European Heart Journal, Istaroxime, MD, Patient, Disease, Therapy, Pharmaceutical industry

WARRINGTON, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced it will host a virtual R&D and Investor Day on Wednesday, June 14, 2023 at 1:00 PM ET. The program will feature the Company’s lead drug candidate, istaroxime, a first in class, dual-acting agent, being developed to treat cardiogenic shock and acute decompensated heart failure. Istaroxime is designed to improve systolic contraction and diastolic relaxation of the heart.

Key Points: 
  • The program will feature the Company’s lead drug candidate, istaroxime, a first in class, dual-acting agent, being developed to treat cardiogenic shock and acute decompensated heart failure.
  • Istaroxime is designed to improve systolic contraction and diastolic relaxation of the heart.
  • Members of Windtree’s leadership team will present istaroxime early cardiogenic shock study data and provide insight into the istaroxime expanded development strategy and planned near-term milestones.
  • Additionally, strategy related to acute heart failure, the follow-on oral, SERCA2a activators and business development will be discussed.

Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent

Retrieved on: 
Monday, April 17, 2023
Patent, Acute decompensated heart failure, IV, Cardiogenic shock, Heart failure, Windtree Therapeutics, HEART, Heart, Opposition procedure before the European Patent Office, LIKE, Patient, European Patent Convention, Therapy, Family, Pharmaceutical industry

3599243, providing patent coverage for the dual mechanism SERCA2a Activator class of drug candidates.

Key Points: 
  • 3599243, providing patent coverage for the dual mechanism SERCA2a Activator class of drug candidates.
  • The new patent, titled: “17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE,” provides patent protection until July 2038 for the family of compounds with a dual mechanism of action.
  • Windtree believes therapies that activate SERCA2a represent a potential important advancement in heart failure treatment for patients,” said Craig Fraser, CEO and President of Windtree Therapeutics.
  • Compounds that activate SERCA2a have been aggressively pursued as much sought-after targets in the treatment of heart failure, and Windtree has found a unique mechanism that activates SERCA2a.”

Aortix Pump Therapy Leads to Rapid Decongestion and Improved Kidney Function in Hospitalized Patients with Heart Failure and Worsening Renal Function

Retrieved on: 
Tuesday, March 21, 2023
Heart, Congestion, Acute decompensated heart failure, Heart failure, MI, CRS, Perfusion, ADHF, FACC, Patient, Swelling, Cardiorenal syndrome, Blood, Abdomen, Mortality, THT, Military Hospital 4/637, Fatigue, Pharmaceutical industry, Medical device, MD

These patients, who were unresponsive to available medical therapy, demonstrated significant improvements in kidney function, cardiac function, and patient-reported assessment of shortness of breath at 30 days after treatment with the Aortix pump.

Key Points: 
  • These patients, who were unresponsive to available medical therapy, demonstrated significant improvements in kidney function, cardiac function, and patient-reported assessment of shortness of breath at 30 days after treatment with the Aortix pump.
  • The results from the CRS pilot study were presented today during the late-breaking clinical science session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.
  • The consistent results indicate the potential of Aortix therapy to be a major therapeutic advancement for CRS patients.
  • The innovative design uses intra-aortic placement and harnesses fluid entrainment to pump blood without the need of a valve and provides physiologically natural delivery of therapy.

Nuwellis Announces Peer-Reviewed Publication of Clinical Trials Analysis Advocating the Use of Ultrafiltration for Heart Failure Patients Resistant to Diuretics

Retrieved on: 
Tuesday, March 21, 2023
Diuretic, Acute decompensated heart failure, IV, Expansion, Ultrafiltration, ADHF, Burn, History, Hospital, Publication, Patient, Pharmaceutical industry

The publication highlights the scale of clinical burden: “ADHF has the highest rate of hospital readmissions among all medical conditions and portends a significant financial burden on healthcare systems worldwide.”1

Key Points: 
  • The publication highlights the scale of clinical burden: “ADHF has the highest rate of hospital readmissions among all medical conditions and portends a significant financial burden on healthcare systems worldwide.”1
    The publication , “Extracorporeal Ultrafiltration for Acute Heart Failure,” featured in Cardiorenal Medicine Journal, includes the review of pooled data from seven randomized controlled trials of ultrafiltration with a total of 771 patient participants.
  • “In the last six months we have announced various new publications demonstrating results that favor ultrafiltration over IV diuretics when using Nuwellis’ Aquadex system.
  • This publication is different because it outlines the reasons why healthcare providers should use ultrafiltration and the consequences of not using it to treat ADHF.
  • We look forward to increased sales momentum as we expand awareness of the benefits of ultrafiltration over diuretics using the arguments presented by the authors.”

Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure

Retrieved on: 
Tuesday, February 28, 2023
Windtree Therapeutics, Metabolite, Therapy, Arrhythmia, Journal of Pharmacology and Experimental Therapeutics, CMO, Istaroxime, Acute decompensated heart failure, Treatment, Journal, Heart failure, Probability, Activity, Relaxation, Human, Calcium, Public health genomics, Cardiogenic shock, Experiment, Pharmaceutical industry, Medical device, Pharmacology

The publication emphasizes the interest in SERCA2a as a target in treating heart failure because it is instrumental in calcium management, critically important in heart muscle contraction and relaxation.

Key Points: 
  • The publication emphasizes the interest in SERCA2a as a target in treating heart failure because it is instrumental in calcium management, critically important in heart muscle contraction and relaxation.
  • Our SERCA2a activators uniquely interfere with phospholamban, a protein that inhibits SERCA2a function and does so excessively in heart failure.
  • The preclinical data discussed in the paper provides rationale for selective targeting of SERCA2A in the treatment of heart failure.
  • “Windtree’s SERCA2a activator drug candidates could represent a promising IV or oral approach to treat heart failure,” said Steve Simonson, CMO of Windtree Therapeutics.

Cordio Medical HearO™ Voice Signature Technology Demonstrates Superior Standard of Care for Heart Failure Patients

Retrieved on: 
Tuesday, November 29, 2022
HEARO, Patient, Hospital, Human, Multimedia, Machine learning, Risk, Physician, Community, Mortality, Heart failure, Heart, Cerebral edema, History of communication studies, Speech, Internal medicine, Acute decompensated heart failure, Smartphone, Ohio State University, Hospital, patients, health, territories, Pharmaceutical industry, Medical device

NEW YORK, Nov. 29, 2022 /PRNewswire/ -- Cordio Medical, a market-leading medical speech processing platform, shared key findings in the HearO™Community Study: Remote Speech Analysis of Hospitalized Patients with Acute Decompensated Heart Failure that assessed remote speech analysis through the Cordio HearO™application. 

Key Points: 
  • Dr. William Abraham , Professor of Internal Medicine at Ohio State University, presented his evaluation of hospitalized patients with acute decompensated heart failure.
  • There are few tools for remote assessment of heart failure clinical status today, particularly when patients are becoming congested and at risk for heart failure hospitalization.
  • The HearO application attempts to meet a significant unmet need in managing heart failure patients.
  • The Cordio HearO application demonstrated an 80% sensitivity for predicting a heart failure event in this population and among those events.